Can Doug and Gilmore use $7 billion - right now? | SRPT Message Board Posts

Sarepta Therapeutics Inc.

  SRPT website

  •  Special $399 Lifetime Membership offer ends soon:
    For anyone who may have missed the memo posted last week, in August of 2018 we offered a limited number of 1-yr options to purchase Lifetime Premium Memberships. Fewer than 2 dozen remain unexercised. Rather than allow them to expire worthless, we are making them available to serious takers on an exclusive
    first come, first served basis. CLICK HERE to lock in a lifetime of benefits & savings!



  • Not sure what all the "Premium Service" fuss is all about? 

    Watch this 2 minute video to find out.





  • Only 11 
    Lifetime Premium Memberships left

SRPT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  13815 of 13864  at  7/16/2019 9:49:32 AM  by

schmiggins


 In response to msg 13814 by  schmiggins
view thread

Re: Can Doug and Gilmore use $7 billion - right now?

That Barron's article is pretty good.

"Instead of embarking on a pharmaceutical megamerger, of the sort Barron’s has argued against, Daniel O’Day, Gilead’s new CEO, signed a 10-year deal with longtime collaborator Galapagos (ticker: GLPG) to boost his company’s pipeline of potential treatments.

–– ADVERTISEMENT ––


“I firmly believe [in] the concept that we’ve come up with, the concept of enabling Galapagos with a significant capital infusion for them to further invest in that research and at the same time keeping their independence as a premier European biotech company that allows them to recruit the very best talent, make their own decision and progress programs according to their judgment,” O’Day said on a conference call about the deal.

The back story. Gilead  (GILD) and Galapagos have had a long courtship. Gilead signed a $2 billion deal with Galapagos in 2015, codeveloping an experimental rheumatoid-arthritis drug called filgotinib. Before the new deal, Gilead had a 12.3% ownership stake in Galapagos. The current agreement will increase that stake to 22%.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 122
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  ï¿½  Contact Us  ï¿½  Follow Us on Twitter  ï¿½  Members Directory  ï¿½  Help Center  ï¿½  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
� 2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...